Frisco, Texas-based 4WEB Medical has appointed Brad Niemann as president.
Brad Niemann Named 4WEB Medical President

An industry veteran, Niemann has over 20 years of experience in the medical technology industry. Over the course of his career he has served as a business leader with a number of orthopedic and spine companies.
Most recently, Niemann served as CEO of Conventus Flower Orthopedics, a provider of foot and ankle surgical solutions. Prior to that, Niemann served as executive vice president for WellAir Solutions.
Niemann also spent nearly eight years with Orthofix and for nearly six years served as president of Global Spine for Orthofix International. Earlier in his career, Niemann held roles of increasing responsibility at Enovis (formerly DJO Global).
When discussing his decision to join 4WEB Medical, Niemann expressed excitement about his new role commenting, “I’ve watched and admired 4WEB Medical for years. I’ve always been impressed with the impact that the company has had on our industry. 4WEB was first to market with 3D printed implants and quite honestly broke down the doors that the rest of the industry is walking through now.”
Niemann continued, “What I am really excited about is contributing to the mission of positively affecting the outcomes of people’s lives through the development of the truss technology. I have firsthand experience seeing the positive reaction from the surgeon community that utilizes 4WEB’s product offering. I am excited to partner with the entire 4WEB team to help drive the organization to greater success.”
4WEB Medical is an orthopedic implant company focused on creating patient-specific solutions. Its proprietary truss implant platform is manufactured with 3D printing technology.
4WEB Medical CEO Jessee Hunt commented, “4WEB is excited to have Brad join the team and lead our organization through our next phase of growth. Since launching our Truss Implant Technology™ in 2012 we have put significant effort in defining the clinical benefits of the truss implant. We are currently finalizing several advanced studies that will further bolster the story and redefine the gold standard for orthopedic implants. We look forward to sharing this data with the industry in the near future.”
Hunt continued, “Brad’s proven leadership in commercial and operational roles, as well as extensive experience managing significant growth, will be invaluable to the company as 4WEB continues to develop and market its differentiated technology.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.